Roche: Strong Obesity Data Fuel Attack on Novo Nordisk and Eli Lilly!

The Swiss pharmaceutical giant Roche has achieved a significant milestone in the global race for dominance in the booming market for obesity therapies. As the company announced on Tuesday in Basel, the hope-filled candidate CT-388 yielded convincing results in a phase II clinical study, which could pose a serious threat to established players Novo Nordisk and Eli Lilly. With this data, Roche underscores its ambitions to establish itself as one of the leading players in this lucrative segment. The significant weight loss of 22.5% and the normalization...